EP Patent

EP0317281A2 — Pharmaceutical formulations containing melphalan or melphalan hydrochloride, as well as melphalan and melphalan hydrochloride and processes for preparing them

Assigned to Wellcome Foundation Ltd · Expires 1989-05-24 · 37y expired

What this patent protects

The present invention relates to a new two-component pharmaceutical formulation of melphalan in which the two components comprise a) freeze-dried mephalan hydrochloride and b) a solvent-diluent comprising a citrate, propylene glycol and ethanol. Substantially pure melphalan, …

USPTO Abstract

The present invention relates to a new two-component pharmaceutical formulation of melphalan in which the two components comprise a) freeze-dried mephalan hydrochloride and b) a solvent-diluent comprising a citrate, propylene glycol and ethanol. Substantially pure melphalan, substantially pure melphalan hydrochloride and methods for preparing them are also described.

Drugs covered by this patent

Patent Metadata

Patent number
EP0317281A2
Jurisdiction
EP
Classification
Expires
1989-05-24
Drug substance claim
No
Drug product claim
No
Assignee
Wellcome Foundation Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.